Phase 2 study comparing the efficacy between afatinib & osimertinib based on immunological biomarker in EGFR-mutant NSCLC

被引：0
|
作者：
Morikawa, Kei [1 ]
Tanaka, Hisashi [2 ]
Takata, Saori [3 ]
Watanabe, Satoshi [4 ]
Kishi, Kazuma [5 ]
Soejima, Kenzo [6 ]
Kaira, Kyoichi [7 ]
Kagamu, Hiroshi [7 ]
Yoshimura, Kenichi [8 ]
Matsutani, Noriyuki [9 ]
Seki, Nobuhiko [10 ]
机构：
[1] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp Med, Kawasaki, Kanagawa, Japan
[2] Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Aomori, Japan
[3] Kyorin Univ, Dept Resp Med, Sch Med, Mitaka, Tokyo, Japan
[4] Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata, Japan
[5] Toho Univ, Omori Med Ctr, Dept Resp Med, Tokyo, Japan
[6] Keio Univ Hosp, Clin & Translat Res Ctr, Tokyo, Japan
[7] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Moroyama, Saitama, Japan
[8] Hiroshima Univ Hosp, Med Ctr Translat & Clin Res, Hiroshima, Japan
[9] Teikyo Univ Hosp, Dept Surg, Mizonokuchi, Japan
[10] Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P68-3
引用
收藏
页码：S538 / S538
页数：1
相关论文
共 50 条
  • [1] Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report
    Morita, R.
    Hata, A.
    Ota, T.
    Sumi, T.
    Yoshioka, H.
    Osugi, J.
    Fujisaka, Y.
    Mitsui, M.
    Morita, S.
    Katakami, N.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S466 - S467
  • [2] Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
    Morikawa, Kei
    Tanaka, Hisashi
    Itani, Hidetoshi
    Takata, Saori
    Watanabe, Satoshi
    Kishi, Kazuma
    Soejima, Kenzo
    Kaira, Kyoichi
    Kagamu, Hiroshi
    Yoshimura, Kenichi
    Matsutani, Noriyuki
    Seki, Nobuhiko
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [3] Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC
    Wang, P.
    Li, Y.
    Lv, D.
    Ding, L.
    Hong, W.
    Han-Zhang, H.
    Lin, J.
    Zhou, J.
    Wang, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S598 - S599
  • [4] Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
    Hata, Akito
    Katakami, Nobuyuki
    Takase, Naoto
    Kibata, Kayoko
    Yamanaka, Yuta
    Tamiya, Motohiro
    Mori, Masahide
    Kijima, Takashi
    Morita, Satoshi
    Sakai, Kazuko
    Nishio, Kazuto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study
    Kian, W.
    Roisman, L. C.
    Chernomordikov, E.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Keren, S.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1100 - S1100
  • [6] The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
    Chang, Allison E. B.
    Piper-Vallillo, Andrew J.
    Mak, Raymond H.
    Lanuti, Michael
    Muzikansky, Alona
    Rotow, Julia
    Jaenne, Pasi A.
    Mino-Kenudson, Mari
    Swanson, Scott
    Wright, Cameron D.
    Kozono, David
    Marcoux, Paul
    Piotrowska, Zofia
    Sequist, Lecia, V
    Willers, Henning
    ONCOLOGIST, 2024, 29 (07): : 609 - 618
  • [7] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
  • [8] Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
    Bertino, Erin M.
    Gentzler, Ryan D.
    Clifford, Sarah
    Kolesar, Jill
    Muzikansky, Alona
    Haura, Eric B.
    Piotrowska, Zofia
    Camidge, D. Ross
    Stinchcombe, Thomas E.
    Hann, Christine
    Malhotra, Jyoti
    Villaruz, Liza C.
    Paweletz, Cloud P.
    Lau, Christie L.
    Sholl, Lynette
    Takebe, Naoko
    Moscow, Jeffrey A.
    Shapiro, Geoffrey, I
    Janne, Pasi A.
    Oxnard, Geoffrey R.
    CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1604 - 1611
  • [9] SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
    Zhou, Q.
    Li, J.
    Wang, J.
    Yang, L.
    Fang, J.
    Dong, X.
    Yi, T.
    Min, X.
    Xu, F.
    Chen, J.
    Zhong, D.
    Bai, J.
    Liu, L.
    Zeng, A.
    Tang, J.
    Wu, H.
    Luo, X.
    Yu, J.
    Su, W.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S429
  • [10] Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational study
    Takase, N.
    Hata, A.
    Sumi, T.
    Yoshioka, H.
    Fujisaka, Y.
    Ota, T.
    Osugi, J.
    Mitsui, M.
    Morita, R.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S811 - S811
12345